Primary Country (Mandatory)

Other Country (Optional)

Set News Language for United States

Primary Language (Mandatory)
Other Language[s] (Optional)
No other language available

Set News Language for World

Primary Language (Mandatory)
Other Language(s) (Optional)

Set News Source for United States

Primary Source (Mandatory)
Other Source[s] (Optional)

Set News Source for World

Primary Source (Mandatory)
Other Source(s) (Optional)
  • Countries
    • India
    • United States
    • Qatar
    • Germany
    • China
    • Canada
    • World
  • Categories
    • National
    • International
    • Business
    • Entertainment
    • Sports
    • Special
    • All Categories
  • Available Languages for United States
    • English
  • All Languages
    • English
    • Hindi
    • Arabic
    • German
    • Chinese
    • French
  • Sources
    • India
      • AajTak
      • NDTV India
      • The Hindu
      • India Today
      • Zee News
      • NDTV
      • BBC
      • The Wire
      • News18
      • News 24
      • The Quint
      • ABP News
      • Zee News
      • News 24
    • United States
      • CNN
      • Fox News
      • Al Jazeera
      • CBSN
      • NY Post
      • Voice of America
      • The New York Times
      • HuffPost
      • ABC News
      • Newsy
    • Qatar
      • Al Jazeera
      • Al Arab
      • The Peninsula
      • Gulf Times
      • Al Sharq
      • Qatar Tribune
      • Al Raya
      • Lusail
    • Germany
      • DW
      • ZDF
      • ProSieben
      • RTL
      • n-tv
      • Die Welt
      • Süddeutsche Zeitung
      • Frankfurter Rundschau
    • China
      • China Daily
      • BBC
      • The New York Times
      • Voice of America
      • Beijing Daily
      • The Epoch Times
      • Ta Kung Pao
      • Xinmin Evening News
    • Canada
      • CBC
      • Radio-Canada
      • CTV
      • TVA Nouvelles
      • Le Journal de Montréal
      • Global News
      • BNN Bloomberg
      • Métro
Manitoba announces availability of Pfizer bivalent; expands eligibility

Manitoba announces availability of Pfizer bivalent; expands eligibility

CTV
Thursday, October 13, 2022 10:00:07 PM UTC

The Manitoba government announced on Thursday that it expects to receive the Pfizer bivalent vaccine by the end of the week, and that it is expanding the eligibility for the bivalent booster vaccine to anyone aged 12 and older.

The Manitoba government announced on Thursday that it expects to receive the Pfizer bivalent vaccine by the end of the week, and that it is expanding the eligibility for the bivalent booster vaccine to anyone aged 12 and older.

In a news release, the province said once the bivalent vaccine arrives in Manitoba, it will be shipped to different clinics, pharmacies and vaccine sites across the province. Delivery dates may vary, so while it may be at some locations earlier, the Pfizer bivalent is expected to be at most vaccine sites by Oct. 24.

Those 18 and older can receive either the Moderna or Pfizer bivalent booster dose, while those aged 12 to 17 can only get the Pfizer bivalent as it is the only one approved for the age group.

To help make things simpler this fall, the Manitoba government is updating how vaccination appointments are booked through the online booking tool or call centre. Manitobans will be able to make a generic vaccination appointment and then will be able to receive a COVID-19 vaccine, a seasonal flu vaccine or both at their appointment.

Appointments for the bivalent vaccine for people aged 12 to 17 will be available beginning on Friday at 9 a.m. through the online booking tool, by contacting the vaccine call centre at 1-844-626-822, or by contacting medical clinics and pharmacies directly.

The province recommends that when making a bivalent dose appointment for the 12 to 17 age group, you should make it for the week of Oct. 24 in order to ensure Pfizer is in stock.

Health Canada approved the use of the Pfizer bivalent vaccine earlier in the month. The Moderna bivalent is already available in Manitoba.

Read full story on CTV
Share this story on:-
More Related News
© 2008 - 2025 Webjosh  |  News Archive  |  Privacy Policy  |  Contact Us